

**Amikar Sehdev, M.D., M.P.H., F.A.C.P.**  
**Curriculum Vitae**  
**Ironwood Cancer & Research Centers, a Division of Ironwood Physicians, PC**

**EMPLOYMENT HISTORY**

06/20-present Ironwood Physicians, PC

- 2014-6/20 Assistant Professor of Clinical Medicine, Division of Hematology Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN
- 10/14-6/20 Adjunct Faculty, Richard M. Fairbanks School of Public Health, Indiana University
- 10/14-6/20 Regenstrief Affiliated Scientist, Regenstrief Institute, Indianapolis, IN
- 7/10-6/11 Instructor, Department of Medicine, University of Utah, Salt Lake City, UT

**ACADEMIC TRAINING**

- 07/97-12/02 Bachelor of Medicine and Bachelor of Surgery (M.B.B.S.), Government Medical College and Hospital (GMCH), Chandigarh, India
- 01/03-06/03 House Officer, Department of Psychiatry, Government Medical College and Hospital (GMCH), Chandigarh, India
- 07/03-07/04 House Officer, Verma Maternity Center, Panchkula, India
- 08/04-06/07 Masters of Public Health (M.P.H.), Northern Illinois University (NIU), DeKalb, IL
- 07/07-06/10 Internal Medicine Residency, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL
- 07/10-06/11 Instructor, Department of Medicine, University of Utah, Salt Lake City, UT
- 07/11-06/14 Fellow, Hematology Oncology, University of Chicago, Chicago, IL
- 07/13-08/13 Fellow, AACR/ASCO Methods in Clinical Cancer Research Workshop, Vail, CO
- 03/13-03/14 Bioinformatics, Center for Research Informatics, University of Chicago, Chicago, IL
- 2013-2014 Coursework in Translational Bioinformatics, Stanford University, Stanford, CA
- 08/14 Fellow, AACR Integrative Molecular Epidemiology Workshop, Boston, MA

**LICENSING AND BOARD CERTIFICATION**

- 2005 Education Commission for Foreign Medical Graduates (ECFMG) Certification
- 2007 Illinois State license
- 2010 American Board of Internal Medicine, Internal Medicine
- 2010 Utah State license
- 2014 American Board of Internal Medicine, Medical Oncology
- 2014 Indiana State license
- 2019 Arizona State license
- 2019 California State license

**HONORS, PRIZES, AND AWARDS**

- 1994 National Merit Scholarship, Chandigarh, India
- 2008 Poster of Distinction, Digestive Disease Week, San Diego, CA
- 2012 Kozloff Fellow of the Year
- 2012 Clinical and Translational Science Award, University of Chicago, Chicago, IL
- 2013 Illinois Medical Oncology Society Fellows Research Competition Winner
- 2016 Heroes Foundation SJP Scholar, Heroes Foundation
- 2017 Fellow of the American College of Physicians (ACP)

**LEADERSHIP**

- 11/16-6/20: Medical Director Oncology Services for the Electronic Medical Record, Indiana University
- Identify and promote best practices, as determined by appropriate evidence

- Measurement and evaluation of current practices and performance to reduce variation from best practices and to enhance service, patient satisfaction, efficiency of care, and efficiency of resource consumption
- Provide supervision for the development of new chemotherapy order sets to support research and clinical care
- Coordinate with Cerner Information Services team to develop new functionality and introduce it to the faculty members
- Oversee Cerner electronic health records functionality, address any operational issues and develop initiatives to enhance the user experience
- Host other health care providers/organization for Cerner tours

01/17-06/20: Indiana Oncology Society (IOS), Board Member-at-Large

- One of 12 members writing National Guidelines for adjuvant treatment of melanoma
- Attend the board meetings of the Society and provide assistance with facilitating meetings
- Attend events for platinum corporate sponsors at membership, conferences and meetings
- Act as Society liaison with pharmaceutical representatives
- Recruit new members into the Society
- Promote Society meetings and other events and perform other duties as required by the Society's Bylaws or requested by the President

01/19-04/20: American Society of Clinical Oncology (ASCO), Melanoma Guidelines Committee

- One of 12 members writing National Guidelines for adjuvant treatment of melanoma

06/19-06/20: Director of the Pancreatic Cancer Program, Indiana University

- Interact with other medical, surgical and radiation oncologist to identify program priorities for research and clinical care
- Oversee clinical research program, collaborate with other investigators and industry to have a portfolio of clinical trials and other translations research projects
- Responsible for pancreatic tumor board
- Attend research and administrative meetings

## **PUBLICATIONS**

Peer-reviewed publications in the primary literature, exclusive of abstracts:

1. Fichera A, **Sehdev A**, Bissonnette M, et al. EGFR Signaling is Required for Microadenoma Formation in the Mouse Azoxymethane Model of Colonic Carcinogenesis. *Cancer Research*. 2007 Jan; 67(2): 827-835
2. Dougherty U, **Sehdev A**, Bissonnette M, et al. EGFR Controls Flat Dysplastic Aberrant Crypt Foci Development and Colon Cancer Progression in the Rat Azoxymethane Model. *Clinical Cancer Research*. 2008 Apr; 14(8): 2253-62
3. Dougherty U, **Sehdev A**, Bissonnette M, et al. EGFR is Required for Colonic Tumor Promotion by Dietary Fat in the Azoxymethane/Dextran Sulfate Sodium Model: Roles of TGF- $\alpha$  and PTGS2. *Clinical Cancer Research*. 2009 Nov; 15(22): 6780-6789
4. **Sehdev A** and Dhoble A. Pulmonary Artery Dissection: A Very Unusual Cause of Chest Pain. *Journal of Hospital Medicine*. 2010 May; 5(5): 313-316
5. Lash A, **Sehdev A** and Plonczynski D. Trends in Hypothesis Testing and Related Variables in Nursing Research: a Retrospective Exploratory Study. 2011; 18 (3): 38-44
6. **Sehdev A**, Wanner N, Pendleton RC. Statins for the Prevention of Venous Thromboembolism? A Narrative Review. *Hosp Pract (Minneap)*. 2012 Aug;40(3):13-8
7. **Sehdev A**, Zhao Y, Singh AK and Sharma N. Primary Small Cell Carcinoma of the Tonsil: A Case Report and Review of the Literature. *Case Rep Oncol*. 2012 Sep;5(3):537-41
8. **Sehdev A** and Catenacci DVT: Gastroesophageal Cancer: Focus on Epidemiology, Classification

- and Staging. *Discovery Medicine* 2013, 16(87):103–111
9. **Sehdev A** and Catenacci DVT: Perioperative Therapy for Locally Advanced Gastroesophageal Cancer: Current Controversies and Consensus of Care. *Journal of Hematology & Oncology* 2013, Sep 5;6(1):66
  10. **Sehdev A** and Polite BP: Modern Chemoradiation and Chemotherapy Protocols for Locally Advanced Rectal Cancer: The Current and Future Standards of Care. *Seminars in Colon and Rectal Surgery* 2013, 24(3):132-141
  11. **Sehdev A**, Shih T, Vekhter B, Lyttle C, Huo D and Polite BP: The Role of Statins for Primary Prevention in Non-elderly Colorectal Cancer Patients. *Anticancer Research* 2014, 34(9): 1-8
  12. **Sehdev A**, Shih T, Vekhter B, Bissonnette MB, Olopade OI and Polite BP. Metformin for Primary Colorectal Cancer Prevention in Diabetic Patients: A Case-Control Study in a US Population. *Cancer* 2014, Nov 25
  13. Valsangkar N, **Sehdev A**, Misra S, Zimmers TA, O'Neil BH, and Koniaris LG. Current management of gastrointestinal stromal tumors: Surgery, current biomarkers, mutations, and therapy. *Surgery*, June 2015
  14. **Sehdev A** and O'Neil BH. The Role of Aspirin, Vitamin D, Exercise, Diet, Statins, and Metformin in the Prevention and Treatment of Colorectal Cancer. *Current Treatment Options in Oncology*. September 2015, 16:43
  15. **Sehdev A**, Cramer H, Ibrahim AA, Younger AE and O'Neil BH. Pathological Complete Response with Anti-PD1 Therapy in a Patient with Microsatellite Instable High, BRAF Mutant Metastatic Colon Cancer: A Case Report and Review of Literature. *Discovery Medicine*. May 22, 2016
  16. **Sehdev A**, Sherer EA, Hui SL, Wu J and Haggstrom DA. Patterns of computed tomography surveillance in survivors of colorectal cancer at Veterans Health Administration facilities. *Cancer*, 2017 Jun 15;123(12):2338-2351
  17. Mamdani H, Wu Howard, O'Neil BH and **Sehdev A**. Excellent Response to Anti-PD-1 Therapy in a Patient with Hepatocellular Carcinoma: Case Report and Review of Literature. *Discovery Medicine* 2017, May;23(128):331-336
  18. Dadi N, Stanley M, Shahda S, O'Neil BH and **Sehdev A**. Impact of Nab–Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer. *Anticancer Research* October 2017 vol. 37 no. 10 5533-5539
  19. **Sehdev A**, Karrison T, Zha Y, Sharma MR et al. A Pharmacodynamic Study of Sirolimus and Metformin in Patients with Advanced Solid Tumors. *Cancer Chemother Pharmacol*. 2018 Aug;82(2):309-317
  20. **Sehdev A**, Gbolahan O, Hancock BA, O'Neil BH et al. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. *Clinical Cancer Research*. DOI: 10.1158/1078-0432.CCR-18-1472
  21. DeWitt JM, Sandrasegaran K, O'Neil B, House MG, Zyromski NJ, **Sehdev A**, Perkins SM, Flynn J, McCranor L, Shahda S. Phase I Study of EUS-guided Photodynamic Therapy for Locally Advanced Pancreatic Cancer. *Gastrointest Endosc*. 2018 Sep 14 [Epub ahead of print]
  22. Milgrom DP, **Sehdev A**, Kays JK, Koniaris LG. Integrating therapies for surgical adult soft tissue sarcoma patients. *Translational Gastroenterology and Hepatology* 2018, 3:88
  23. Gbolahan OB, Tong Y, **Sehdev A**, O'Neil BH, Shahda S. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study. *BMC Cancer*. 2019 May; 19 (1): 468
  24. Joshi SS, Catenacci DVT, Karrison TG, Peterson JD, Zalupski MM, **Sehdev A** et al. 5-fluorouracil/leucovorin, nab-paclitaxel, and irinotecan with UGT1A1 genotype-guided dosing (FOLFIRABRAX) in untreated patients with gastrointestinal malignancies. Accepted in *Clinical Cancer Research* July 24, 2019
  25. Patel AS, Snook RJ, Sehdev A. Chronic Inflammatory Demyelinating Polyradiculoneuropathy Secondary to Immune Checkpoint Inhibitors in Melanoma Patients. *Discovery Medicine* 2019, Aug; 28(152)

Book chapters:

**Sehdev A** and Marsh R. Contribution of Chemotherapy to the Toxicity of Pelvic Irradiation. Book Chapter. Radiation Therapy for Pelvic Malignancy and its Consequences. Editors, Ehrenpreis, Marsh and Small. Publisher, Springer. Publication date, August 2014

Non-peer-reviewed original articles

1. **Sehdev, A.** Genetics and Cancer Prevention: Focus on Colorectal Cancer. Website: <http://biochem158.stanford.edu/Final%20Papers%202013/Sehdev.pdf>
2. **Sehdev, A.** ASCO MedPage Today Expert Critique. Melanoma Gene-expression Biomarker Predicts Immunotherapy Response. Website: <https://www.medpagetoday.com/reading-room/asco/skin-cancer/75813>. Dated Oct 20, 2018
3. **Sehdev, A.** ASCO MedPage Today Expert Critique. Improved Immunotherapy Response in Melanoma Patients with Genetic Mutations. Website: <https://www.medpagetoday.com/reading-room/asco/immunotherapy/76193>. Dated Nov 8, 2018
4. **Sehdev, A.** ASCO MedPage Today Expert Critique. Liquid Biopsy and MSI in Multiple tumors. Website: <https://www.medpagetoday.com/reading-room/asco/immunotherapy/82392>. Dated Sept 9, 2019
5. **Sehdev, A.** ASCO MedPage Today Expert Critique. Long-Term QOL for Melanoma Patients on Immunotherapy. Website: <https://www.medpagetoday.com/reading-room/asco/immunotherapy/83066>. Dated Oct 31, 2019
6. **Sehdev, A.** ASCO MedPage Today Expert Critique. BRAF-Mutated Metastatic Melanoma: Recent Research Context. Website: <https://www.medpagetoday.com/reading-room/asco/skin-cancer/83507>. Dated Nov 23, 2019

**PRESENTATIONS**

1. PKC-Delta Mediates Pro-Inflammatory Responses in RAW-264.7 Macrophage Cells and Is Down-Regulated in Human Colon Cancer Stromal Cells. Presented at: Digestive Disease Week 2007; Washington, DC
2. EGFR Controls Flat Dysplastic ACF Development and Colon Cancer Progression in the Rat Azoxymethane Model. Presented at: Digestive Disease Week 2008-Poster of Distinction; San Diego, CA
3. A Case of Pulmonary Sequestration. Presented at: American College of Physicians Northern Illinois Meeting; Maywood, IL
4. The Role of Statins for Primary Prevention in Non-elderly Colorectal Cancer Patients. Presented at: 2013 American Society of Clinical Oncology, Annual Meeting, Chicago, IL
5. The Role of Metformin for Primary Prevention in Non-elderly Diabetic Colorectal Cancer Patients. Presented at: 2014 GI Cancers Symposium, San Francisco, CA
6. The Role of Statins for Primary Prevention in Non-Elderly Colorectal Cancer Patients. Presented at: Outcomes Research Workshop, Center for Health and the Social Sciences, University of Chicago, Chicago, IL. 2013.
7. Statins in Colorectal Cancer Patients. Presented at: Illinois Medical Oncology Society Annual Meeting, Chicago, IL. 2013.
8. Metformin: Role as a Potential Chemopreventive and Therapeutic Agent in Colorectal Cancer. Presented at: Washington University, St. Louis, MO. 2014.
9. Metformin: Role as a Potential Chemopreventive and Therapeutic Agent in Colorectal Cancer. Presented at: Indiana University, Indianapolis, IN. 2014.
10. Possible Targets of Metformin in Colorectal Cancer. Presented at: 2014 American Association for Cancer Research (AACR) Annual Conference on Frontiers in Cancer Prevention Research, New Orleans, LA
11. The Quality of CT Surveillance in Resected Colorectal Cancer survivors at Veterans Health

- Administration Facilities. Presented at: 2016 Gastrointestinal Cancer Symposium, San Francisco, CA
12. Neoadjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer. Presented at: 2016 AACR Special Conference on Pancreatic Cancer. Orlando, FL
  13. Demographic, Clinical and Outcomes Characteristics Associated with Screening Colonoscopy in Colorectal Cancer Patients. Presented at: 2017 Gastrointestinal Cancer Symposium, San Francisco, CA.
  14. Impact of Nab-paclitaxel-based Second Line Chemotherapy on the Outcomes of Pancreatic Cancer. Presented at: 2017 Gastrointestinal Cancer Symposium, San Francisco, CA.
  15. Survival After Recurrence Following Curative Intent Resection of Pancreatic Adenocarcinoma. Presented at: 2017 American Society of Clinical Oncology, Annual Meeting, Chicago, IL
  16. A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer. Presented at: 2017 American Society of Clinical Oncology, Annual Meeting, Chicago, IL.
  17. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Presented at: 2017 American Society of Clinical Oncology, Annual Meeting, Chicago, IL
  18. A Phase Ib/2 study of cancer stemness inhibitor Napabucasin (BBI-608) in combination with Gemcitabine (Gem) & nab-Paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts). Presented at: 2017 ESMO, Barcelona, Spain.
  19. The Impact of Research Presented at Annual Gastrointestinal Cancers Symposium. Presented at: 2018 GI Cancers Symposium, San Francisco, CA
  20. Prognostic role of BRAF mutation in malignant cutaneous melanoma. Presented at: 2018 American Society of Clinical Oncology, Annual Meeting, Chicago, IL.
  21. Safety and tolerability of FOLFIRABRAX [5-Fluorouracil (5-FU), irinotecan (IRI), and nab-paclitaxel (NP)] with genotype-guided dosing of IRI in previously untreated advanced gastrointestinal (GI) cancer patients (pts): A multicenter trial of the University of Chicago Personalized Cancer Care Consortium. Presented at: 2018 American Society of Clinical Oncology, Annual Meeting, Chicago, IL.
  22. A phase II trial of cabozantinib and erlotinib for patients with EGFR and c-MET co-expressing metastatic pancreatic adenocarcinoma. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Presented at: 2018 American Society of Clinical Oncology, Annual Meeting, Chicago, IL.
  23. Association of RAS mutations with Race in Metastatic Colorectal Cancer CALGB 80405 (ALLIANCE). Presented at: 2018 GI Cancers Symposium, San Francisco, CA
  24. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. Presented at: 2018 ESMO, Munich, Germany.
  25. Neoadjuvant therapy duration and outcome of patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC). Presented at: 2019 at Annual Gastrointestinal Cancers Symposium, San Francisco, CA

### **CLINICAL TRIALS**

NCT04046887/Lonsurf Study 2019-Ongoing  
Taiho Oncology, Inc.

Phase I Study of Lonsurf Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Ductal Adenocarcinoma (PDAC)  
Role: Site Co-PI

NCT04005339/NAPOLI-2 2019-Ongoing  
Ipsen Biopharmaceuticals, Inc.

Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated

Amikar Sehdev, M.D., M.P.H., F.A.C.P.

Advanced Biliary Tract Cancer (NAPOLI-2)

Role: Site PI

NCT03941093/LAPIS study

2019-Ongoing

FibroGen

A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer

Role: Site PI

NCT02339571

2017-Ongoing

ECOG-ACRIN/ECOG-ACRIN Cancer Research Group EA6141

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab

Role: Site PI

NCT02965716

2018-Ongoing

SWOG (Southwest Oncology Group) S1607

A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) and Pembrolizumab in Patients with Advanced Melanoma who have progressed on Anti-PD1/L1 based Therapy

Role: Site PI

NCT02519348

2018-Ongoing

MedImmune, LLC

A Study of Safety, Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy, or Durvalumab in Combination with Tremelimumab or Bevacizumab in Subjects with Advanced Hepatocellular Carcinoma

Role: Site Co-I

NCT03233711

2018-Ongoing

ECOG-ACRIN Cancer

A Randomized Phase II Study of Nivolumab After Combined Modality Therapy in High Risk Anal Cancer

Role: Site Co-I

NCT03099564

2017-Ongoing

Hoosier Cancer Research Network (HCRN), Inc.

A Pilot Study of Pembrolizumab in Combination with Y90 Radio-embolization in Subjects with Poor Prognosis Hepatocellular Carcinoma with Preserved Liver Function HCRN

Role: Site Co-I

NCT03213626

2018-Ongoing

Exelixis

A phase II trial of cabozantinib erlotinib for patients with EGFR and c-Met co-expressing metastatic pancreatic adenocarcinoma

Role: Site Co-I

NCT03442569

2018-Ongoing

Hoosier Cancer Research Network (HCRN), Inc.

Phase II multicenter trial of panitumumab, nivolumab, and ipilimumab for KRAS/NRAS/BRAF wild-type MSS refractory metastatic colorectal adenocarcinoma

Amikar Sehdev, M.D., M.P.H., F.A.C.P.

Role: Site Co-I

NCT02138617 2018-Ongoing

Hoosier Cancer Research Network (HCRN), Inc.

A Genotype-directed Phase II Study of Irinotecan Dosing in Metastatic Colorectal Cancer (mCRC)

Patients Receiving FOLFIRI + Bevacizumab

Role: Site Co-I

NCT02145559/ SIROMET 2013-2016

A Pharmacodynamic Study of Sirolimus and Metformin in Patients with Advanced Solid Tumors

Role: PI

GI14-191 2016-2018

Hoosier Cancer Research Network/Bayer HealthCare Pharmaceuticals, Inc.

A Randomized, Phase II Trial to Evaluate the Efficacy of Supportive Therapy with Ginseng for Patients on Treatment with Regorafenib

Role: Site PI

PCCC14-0595 2016-2019

Celgene

A genotype-guided dosing study of FOLFIRABRAX in previously untreated patients with advanced gastrointestinal malignancies

Role: Co-PI

CINC280A2108 2016-2017

Novartis Pharmaceuticals Corporation

A multicenter, open label, phase 1 dose escalation study to evaluate the pharmacokinetics, safety, and tolerability of INC280 tablet with food in patients with cMET dysregulated advanced solid tumors

Role: Site PI

#### **OTHER FUNDING**

U01 10/2018-Ongoing

NIH/NIDDK

Drug Induced Liver Injury Network

Role: Co-I (5% effort)

Walther Cancer Foundation (WCF# 4487513) 2014-Ongoing

Molecular Links between Obesity and Colorectal Cancer Outcomes

Role: PI

Heroes Foundation 2016-Ongoing

Renin Angiotensin System Inhibitors and colorectal cancer

Role: PI

University of Chicago Comprehensive Cancer Center (P30CA014599) 2014-2015

A Pharmacodynamic Study of Sirolimus and Metformin in Patients with Advanced Solid Tumors

Role: Co-PI

Pilot funding, University of Chicago Comprehensive Cancer Center (6-91158) 2012-2014

A Case Control Study of Metformin in Colorectal Cancer

Role: Co-PI

**SERVICE**

- 2011 Interviewer of residency applicants, University of Utah, Salt Lake City, UT
- 2012 Internal auditor for clinical trial protocol adherence
- 2013 Fellow representative for the Fellowship Program Review Committee
- 2014- Reviewer, Scientific Review Committee, Indiana University
- 2014- Ad Hoc Reviewer, Cancer, Cancer Epidemiology, Biomarkers and Prevention, Cancer Research, Journal of the National Comprehensive Cancer Network, BMC Cancer, Cancer Management and Research, Pancreas, Annals of Surgical Oncology, others
- 2016- Indiana Oncology Society, Board Member-at-Large
- 2016- Scientific Advisory Board, Eli Lilly and Company
- 2017- American Society of Clinical Oncology  
ASCO melanoma guidelines committee member  
ASCO Reading Room committee member  
and Journal and Peer Reviewers Group
- 2018- Scientific Advisory Board, Incyte Corporation/Cardinal Health
- 2018- Scientific Advisory Board, Eisai Inc.
- 2018- Scientific Advisory Board, Array BioPharma

**OTHER EXPERIENCE/PROFESSIONAL MEMBERSHIPS**

- 2006- American Public Health Association (APHA)
- 2007- American College of Physicians (ACP)
- 2008-2010 Phi Beta Delta- Zeta Gamma Chapter (Honor Society for International Scholars)
- 2011- American Society of Clinical Oncology (ASCO)
- 2018- Technology Research Group committee member
- 2012-2014 American Medical Informatics Association (AMIA)
- 2013- American Association for Cancer Research (AACR)
- 2015- Society for Immunotherapy of Cancer (SITC)